Skip to main content

Advertisement

Fig. 6 | Journal of Translational Medicine

Fig. 6

From: Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer

Fig. 6

Efficacy of ASO and cisplatin (CDDP) singly and in combination was tested in TKO-002, a PDX model of platinum refractory SCLC. Kaplan–Meier survival curves for animal groups treated with vehicle, ASO (7.5 mg/kg i.p. daily), cisplatin (3 mg/kg i.p. weekly) and the combination of ASO plus cisplatin. There was significant toxicity with rapid death of mice treated with ASO alone or in combination with cisplatin (top). A reduced dose of ASO (3.75 mg/kg every other day) was better tolerated but showed negligible efficacy and failed to potentiate the minimal growth inhibition achieved by cisplatin (3 mg/kg i.p. weekly) in this PDX model derived from a patient with platinum resistant SCLC (middle and bottom panel)

Back to article page